-activated Cl − channels (CaCCs) are expressed abundantly in many eukaryotic cell types, and they are involved in the regulation of various physiological processes, such as epithelial fluid secretion, neuronal and cardiac excitability, oocyte fertilization, and vascular tone regulation. 1, 2 Although CaCCs have been studied at the functional level for >30 years, the molecular identity of this channel remained unclear until 2008, when 3 independent research groups found that TMEM16A (Ano1), a member of the TMEM16 family (TMEM16A-H, TMEM16J, and TMEM16K), was a component of CaCCs. [3] [4] [5] Subsequent studies revealed that TMEM16A was responsible for native CaCCs in numerous cell types, including smooth muscle cells, 6 epithelial cells, 7 interstitial cells of Cajal, 8 gland acinar cells, 9 sensory neurons, 10 and vascular endothelial cells.
11
About the cardiovascular system, previous studies have found that TMEM16A mediated cerebrovascular remodeling, 6 ventricular hypertrophy, 12 pulmonary hypertension, 13 and blood pressure regulation. 14 Recently, it was reported that TMEM16A existed in mouse cardiac vascular endothelial cells and might play a role in the pathophysiological process of cardiac ischemia. 11 However, it remains unclear whether TMEM16A contributes to endothelial dysfunction and regulates blood pressure on hypertensive challenges.
It is well established that increased reactive oxygen species (ROS) formation is associated with endothelial dysfunction, which is a key feature of cardiovascular diseases, including hypertension, atherosclerosis, and diabetes mellitus. 15 In recent years, it has been demonstrated that the NADPH oxidase, whose sole identified function is to generate ROS, is a predominant source of ROS in the vasculature. 15 To date, 7 members (Nox1, Nox2, Nox3, Nox4, Nox5, Duox1, and Duox2) of NADPH oxidase have been
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identified, among which the expression of Nox1, Nox2, Nox4, and Nox5 is largely confined to endothelial cells, and these members might be involved in the development of hypertension. 16 Therefore, the appropriate modulation of ROS production will help to improve endothelial dysfunction in hypertension.
In this study, we generated TMEM16A endothelialspecific knockout and transgenic mice and investigated the specific involvement of TMEM16A in regulating endothelial function and blood pressure via vascular oxidative stress.
Methods
The reagents, cell isolation and culture, adenoviral infection, plasmid transfection, siRNA transfection, reverse transcriptionpolymerase chain reaction, Western blotting, coimmunoprecipitation, cell fractionation, current recording, immunofluorescence, detection of ROS production, measurement of superoxide dismutase (SOD) and glutathione peroxidase (GPx) activities, NADPH oxidase activity assay, generation of endothelial-specific TMEM16A knockout and transgenic mice, animal model, assay of vasorelaxation, and statistical analyses are described in detail in the onlineonly Data Supplement.
All statistical analyses were performed using GraphPad Prism 5 (GraphPad software, La Jolla, CA). All data are expressed as the mean±SD. n represented the number of independent experiments on different batches of cells or different mice. A 2-tailed Student t test for independent samples was used to detect significant differences between 2 groups. One-way or 2-way ANOVA followed by Bonferroni multiple comparison test was used to compare differences when there were >2 treatment groups. The interaction in 2-way ANOVA was considered. The level for statistical significance was 0.05.
Results
TMEM16A Is a Critical Component of CaCCs in Endothelial Cells
Reverse transcription-polymerase chain reaction analysis showed that in human umbilical vein endothelial cells (HUVECs), the transcripts of the TMEM16 family, including TMEM16A, TMEM16B, TMEM16D through TMEM16F, TMEM16H, and TMEM16K, were present; others (TMEM16C, TMEM16G, and TMEM16J) were not detected ( Figure 1A ). The results of the Western blot analysis demonstrated that TMEM16A was expressed abundantly in HUVECs ( Figure 1B) . Confocal image analyses revealed that TMEM16A was distributed widely in both the cell membrane and cytoplasm in HUVECs stained with anti-TMEM16A antibody ( Figure 1C ) or in HUVECs infected with RFP-labeled TMEM16A adenovirus (Ad; Figure 1D) ] i ) of 500 nmol/L exhibited outward rectification and time-dependent relaxation. The reversal potential of this current was −0.51±3.78 mV, which was near the equilibrium potential for Cl − (0 mV) under our experimental conditions. T16A inh -A01 (10 μmol/L), a specific inhibitor of TMEM16A, 17 significantly inhibited this current ( Figure S1 in the online-only Data Supplement). Moreover, Ad-TMEM16A shRNA and Ad-TMEM16A were used to silence or overexpress TMEM16A, respectively, in HUVECs (Figures S2 and S3 present infection efficiency). The results showed that silencing TMEM16A with Ad-TMEM16A shRNA (100 multiplicity of infection) for 48 hours significantly decreased the I Cl,Ca ( Figure 1E ), whereas overexpressing TMEM16A with Ad-TMEM16A (100 multiplicity of infection) for 48 hours further increased this current ( Figure 1F ). These results indicate that TMEM16A is responsible for the I Cl,Ca in HUVECs, whose characteristics are similar to the I Cl,Ca in other cell types. [3] [4] [5] [6] 11 
TMEM16A Is Involved in Ang II-Induced Endothelial Dysfunction
As shown in Figure 2A and 2B, the expression of TMEM16A significantly increased in both HUVECs and aortic endothelium on angiotensin II (Ang II)-induced challenges. Moreover, Ang II significantly increased the I Cl,Ca in HUVECs ( Figure S4 ). Figure 2E ), whereas Ang II-induced endothelial dysfunction was further potentiated in the aortas from TM ETg compared with those from TM con ( Figure 2F ). In addition, almost all of the endothelium-dependent relaxation responses were blocked by L-nitro-arginine methyl ester (1 μmol/L), a nonselective NO synthase inhibitor, and there was no difference between TM EKO , TM ETg , and their control littermates ( Figure S7A and S7B). Moreover, there was no difference in the endothelium-independent vasorelaxation responses induced by sodium nitroprusside among all groups ( Figure S7C and S7D). These findings suggest that TMEM16A is a crucial regulator of both endothelial function and blood pressure.
TMEM16A Is Involved in Ang II-Induced ROS Generation
Overwhelming evidence suggests that Ang II induces ROS production in the vascular wall, resulting in endothelial dysfunction. 18 Thus, we explored whether TMEM16A could affect Ang II-induced ROS generation. Amplex Red, dihydroethidium, and 2′,7′-dichlorodihydrofluorescein diacetate were selected to examine ROS generation. The results showed that ROS production was elevated in the aortas from Ang IIinduced hypertensive mice. Endothelial-specific knockdown of TMEM16A remarkably reduced Ang II-induced ROS production in the aortas ( Figure 3A ; Figure S8A and S8C), whereas endothelial-specific overexpression of TMEM16A showed the opposite effects ( Figure 3B ; Figure S8B and S8D).
To further confirm these results, ROS generation was detected in HUVECs infected with Ad-TMEM16A shRNA or Ad-TMEM16A. Although there was no difference in basal ROS production, Ang II-induced ROS generation was significantly reduced by the silencing of TMEM16A in HUVECs ( Figures  S9A, S10A , and S10C) and was further increased by the overexpression of TMEM16A ( Figures S9B, S10B, and S10D ). In addition, N-acetyl-L-cysteine, a ROS scavenger, significantly decreased Ang II-induced ROS production to the basal level, suggesting that the ROS measurements in the study were reliable ( Figure S11 ). These results further indicate that TMEM16A mediates Ang II-induced ROS generation in endothelial cells.
Endogenous antioxidant enzymes, such as GPx and SOD, are important enzymes that scavenge intracellular ROS under physiological conditions. 15 As shown in Figure S12 , Ang II decreased the activities of GPx and SOD. The silencing of TMEM16A expression reversed the inhibitory effect of Ang II on GPx and SOD. However, the overexpression of TMEM16A enhanced the inhibitory effect of Ang II on GPx and SOD.
TMEM16A Potentiates ROS Generation via Nox2-Containing NADPH Oxidase
Numerous studies have shown that NADPH oxidases are a major source of ROS production in the vasculature. 15, 16 Therefore, the roles of TMEM16A in Ang II-induced NADPH oxidase activation were examined using lucigeninbased enhanced chemiluminescence. The membrane fractions were used for measurements of NADPH oxidase activity to avoid interference by other sources of ROS, such as NO synthases, mitochondria, and xanthine oxidase. Figure 3C and 3D shows that Ang II increased the NADPH oxidase activity in HUVECs, which was inhibited by the silencing of TMEM16A and further enhanced by the overexpression of TMEM16A.
The endothelial abundant Noxes include Nox1, Nox2, Nox4, and Nox5. 15 Next, we determined which of these Noxes were responsible for TMEM16A-related NADPH oxidase activation. Figure S13 shows that the transfection of the siRNA of different Noxes, including Nox1, Nox2, Nox4, and Nox5, in all cases efficiently decreased the respective endogenous Nox protein expression in HUVECs. However, only the knockdown of Nox2 protein expression significantly reversed the effect of TMEM16A on Ang II-induced NADPH oxidase activation ( Figure 3E ).
TMEM16A Increases the Protein Levels of Nox2 and p22phox
Nox2-containing NADPH oxidase is a multisubunit complex, consisting of the membrane-bound catalytic Nox2 subunit and p22phox subunit and 3 cytosolic regulatory subunits: p47phox, p67phox, and Rac1. 15 The expression of these subunits was examined in HUVECs. The results showed that Ang II significantly increased the expression of Nox2 and p22phox, which was attenuated by the silencing of TMEM16A and potentiated by the overexpression of TMEM16A. However, the expression of p47phox, p67phox, and Rac1 induced by Ang II was comparable after the silencing or overexpression of TMEM16A ( Figure S14 ).
The role of TMEM16A in the expression of NADPH oxidase subunits was then investigated in TMEM16A endothelial-specific knockout and transgenic mice. As shown in Figure 4 , the increased expression of Nox2 and p22phox induced by Ang II was reduced in the aortas from TM EKO compared with those from TM WT and increased in the aortas from TM ETg compared with those from TM con . In addition, the expression of p47phox, p67phox, and Rac1 was not different in the aortas from Ang II-induced hypertensive TM EKO and TM ETg compared with those from their control littermates. To differentiate the effects between the vascular endothelium and vascular smooth muscle, cultured mouse aortic endothelial cells were used. The results in endothelial cells were consistent with those in the aortas ( Figure S15 ). Taken together, these results from in vitro and in vivo experiments indicate that TMEM16A promotes Nox2-containing NADPH oxidase activity via increasing the expression of Nox2 and p22phox.
TMEM16A Inhibits Nox2 Protein Degradation
To explore how TMEM16A regulates Nox2 expression in endothelial cells, we evaluated the mRNA expression of Nox2 in HUVECs. As shown in Figure 5A and 5B, the mRNA levels of Nox2 were increased by Ang II, but were comparable between TMEM16A-silenced or TMEM16A-overexpressing cells and their control cells, suggesting that the alteration of the Nox2 protein level by TMEM16A was not because of the regulation of Nox2 protein synthesis. TMEM16A might influence Nox2 protein degradation.
Normally, Nox2 and p22phox form a heterodimer in the membrane, which is essential for the stability of these proteins. If not dimerized, Nox2 and p22phox are presumed to be quickly degraded through a proteasome-dependent endoplasmic reticulum-associated degradation pathway. 19, 20 Our results also showed that the degradation of Nox2 was inhibited by the proteasome inhibitor MG132 but not the lysosome blocker chloroquine ( Figure S16 ). Moreover, MG132 normalized the difference in Nox2 protein expression between the control and TMEM16A-deficient or TMEM16A-overexpressing HUVECs ( Figure 5C and 5D ). After the treatment with cycloheximide (100 μg/mL) to block de novo protein synthesis, TMEM16A overexpression reduced the rate of Nox2 protein degradation, whereas TMEM16A knockdown increased the rate of Nox2 protein degradation ( Figure S17 ). These data suggest that TMEM16A inhibited the degradation of Nox2 through the proteasome-dependent pathway and therefore increased Nox2 protein levels in endothelial cells.
To better understand how TMEM16A regulates the degradation of Nox2, we examined whether TMEM16A interacts with the Nox2-containing NADPH oxidase's subunits. Interestingly, the coimmunoprecipitation of Nox2 by TMEM16A was detected in HUVECs, but not for the other subunits, including p22phox, p47phox, p67phox, and Rac1 ( Figure 5E ). In addition, Ang II significantly increased the protein interaction between TMEM16A and Nox2 in HUVECs ( Figure S18) .
Because neither the Nox2 nor the p22phox monomer was stable in primary endothelial cells and because TMEM16A only interacted with Nox2 and not with p22phox, we further studied their interaction in HEK293T cells. As shown in Figure 5F , on the ectopic overexpression of RFP-tagged TMEM16A, together with flag-tagged Nox2 and His-tagged p22phox, there was a specific interaction between TMEM16A and Nox2, but not between TMEM16A and p22phox ( lanes  1, 2, and 4, top panel) . On the other hand, Nox2 could form a heterodimer with either TMEM16A or p22phox (lanes 2-4, middle panel). Notably, p22phox reduced the interaction between TMEM16A and Nox2 (lanes 2 and 4, top and middle panels). Consistent with the previous results that TMEM16A facilitated Ang II-induced protein upregulation in both Nox2 and p22phox ( Figure 4D ; Figures S14D and S15D) , the coexpression of TMEM16A with Nox2 and p22phox together also led to a substantial increase in protein expression for both Nox2 and p22phox (lanes 3 and 4, bottom panels), but the expression of TMEM16A remained unchanged in each group transfected with TMEM16A (lanes 1, 2, and 4, bottom panels). Together, these data suggested that TMEM16A protected against the degradation of Nox2 by competitively binding with Nox2 against p22phox and forming a relatively stable TMEM16A-Nox2 complex.
TMEM16A Increases the Translocation of p47phox and p67phox
The translocation of p47phox and p67phox from the cytoplasm to the cell membrane is a crucial mechanism for Nox2 activation, 15 and based on our previous results that TMEM16A upregulated Nox2 protein expression, we further examined whether the translocation of p47phox and p67phox was also increased. As shown in Figure 6A and 6B, knockdown of TMEM16A decreased the Ang II-induced translocation of both p47phox and p67phox from the cytoplasm to the cell membrane in HUVECs, whereas the overexpression of TMEM16A produced the opposite effect. Moreover, Ang IIinduced interactions between Nox2 and p47phox, or p67phox, were remarkably attenuated by the knockdown of TMEM16A and further potentiated by the overexpression of TMEM16A ( Figure 6C and 6D) . These results indicate that TMEM16A facilitates the translocation of p47phox and p67phox from the cytoplasm to the cell membrane and the subsequent association with Nox2 in endothelial cells.
Discussion
In this study, we developed novel transgenic mouse models with the targeted knockout or overexpression of TMEM16A in the endothelium to investigate the specific role of endothelial TMEM16A in regulating vascular oxidative stress and hemodynamic responses. The major findings of this study are as follows: (1) TMEM16A is a crucial component of CaCCs in endothelial cells; (2) TMEM16A endothelial-specific knockout leads to a decrease in blood pressure and a protective effect on endothelial function on Ang II-induced hypertension, whereas the endothelial-specific TMEM16A transgene shows the opposite effect; (3) Ang II-induced ROS generation and NADPH oxidase activation in endothelial cells are regulated by TMEM16A; and (4) These effects of TMEM16A on ROS generation and NADPH oxidase activation are because of the upregulation of the Nox2 protein level, which TMEM16A directly binds to and stabilizes. These findings provide important insights into the role of endothelial TMEM16A in vascular ROS production. It is known that Ang II induces ROS production via Nox-derived ROS signaling, resulting in endothelial dysfunction. 15, 21 Previous studies have shown that several types of Cl − channels are related to ROS generation, such as the cystic fibrosis transmembrane regulator, 22 volume-regulated Cl − channel, 23 ClC-1 Cl − channel, 24 and pH-activated Cl − channel. 25 However, the relationship between CaCCs and oxidative stress remained unclear. The results from this study revealed that TMEM16A was responsible for CaCCs in endothelial cells and distributed in both the cell membrane and cytoplasm, suggesting that TMEM16A might play a role in endothelial functions as do other Cl − channels. Therefore, we generated novel transgenic mouse models directing TMEM16A knockout or overexpression to the endothelium under the control of the murine Tie2 promotor. With these mice, we were able to assess the importance of endothelial-specific responses to TMEM16A independent of those of the vascular smooth muscle and adventitia. As predicted, the change in TMEM16A protein expression was detected only in the vascular endothelium and not in other tissues, indicating that the transgenic modification had no effect on other tissues aside from the endothelium.
There are several sources of ROS in the vasculature, but the only enzymes whose sole identified function is to generate ROS are NADPH oxidases. 15 Of the 7 members (Nox1-5, Duox1, and 2) of NADPH oxidases that are expressed in blood vessels, Nox2-containing NADPH oxidase predominantly exists in endothelial cells and is a major source of the excessive ROS production during hypertension.
16 Nox2-containing NADPH oxidase is a multisubunit flavoprotein complex in endothelial cells, consisting of the membrane-bound catalytic Nox2 subunit and p22phox subunit and 3 cytosolic regulatory subunits: p47phox, p67phox, and Rac1. 15 In this study, we found that TMEM16A enhanced Nox2-containing NADPH oxidase activity and increased the protein levels of Nox2 and p22phox induced by Ang II, whereas the expression of p47phox, p67phox, and Rac1 was not changed. These results from cell culture experiments were consistent with those from experiments with TMEM16A endothelial-specific knockout and transgenic mice, indicating that TMEM16A facilitated ROS generation via increasing Nox2-containing NADPH oxidase activity in the vascular endothelium.
It was well established that the protein expression of Nox2 and p22phox is upregulated in response to Ang II in the cardiovascular system, including the aorta, heart, and resistance arteries. 15, 26, 27 Nox2 and p22phox form a heterodimer in the membrane, which is essential to the stability of these proteins. 19, 20 If not dimerized, Nox2 and p22phox are presumed to be quickly degraded through a proteasome-dependent endoplasmic reticulum-associated degradation pathway. 28 Consistent with these findings, our results revealed that the expression of both Nox2 and p22phox was upregulated on Ang II-induced hypertensive challenges. Moreover, the silencing of TMEM16A was associated with the marked upregulation of Nox2 protein degradation via the proteasome-dependent endoplasmic reticulum-associated degradation pathway, whereas the overexpression of TMEM16A had the opposite effect, indicating that TMEM16A played a role in stabilizing Nox2 protein levels. Interestingly, TMEM16A had a direct interaction with Nox2, but not p22phox, suggesting that TMEM16A might compete with p22phox to form a more stable TMEM16A-Nox2 complex to avoid Nox2 degradation. A recent study also reported that a protein named negative regulator of ROS limited ROS generation by directly interacting with the Nox2 monomer, but not p22phox, which facilitated the degradation of Nox2 through the endoplasmic reticulum-associated degradation pathway. 29 Therefore, we speculated that TMEM16A might combine with Nox2 against p22phox and protect against Nox2 degradation.
It is well known that the renin-angiotensin system plays an important role in the control of arterial blood pressure. 30, 31 Ang II, a major member in this system, is involved in the pathogenesis of hypertension, which is in part mediated by vascular NADPH oxidase-derived ROS. 15, 18 For example, basal blood pressure is reduced in Nox2-deficient mice. 32 A subpressor dose of Ang II was shown to have a smaller effect in Nox2 knockout mice compared with wild-type mice. 33 A previous study reported that transgenically overexpressed Nox2 in the endothelium of mice further supported a significant pressor response induced by Ang II compared with that in wild-type mice, although there was no change in the basal blood pressure. 34 In this study, it was noteworthy that the aortic relaxation responses were partially restored in TMEM16A endothelial-specific knockout mice but further deteriorated in TMEM16A endothelial-specific transgenic mice during Ang II-induced hypertension, in combination with the corresponding pressor responses. Moreover, these effects were related to the change in Nox2 protein expression. Actually, TMEM16A-mediated CaCCs have been reported to potentiate membrane depolarization in response to vasoconstrictors and enhance pulmonary vasoreactivity in pulmonary hypertension. 13, 35 Another study suggested that T16A inh -A01, a specific TMEM16A inhibitor, 17 blocked CaCCs in vascular smooth muscle cells (VSMCs) and directly relaxed blood vessels. 36 Recently, a study showed that mice lacking vascular TMEM16A had a lower systemic blood pressure and reduced hypertensive response after administration of vasoconstrictors. 14 The results of all of these studies are consistent with those of this study, and we further found that the upregulation of endothelial TMEM16A aggravated Ang II-induced endothelial dysfunction and hypertension by activating Nox2-containing NADPH oxidases.
Our findings have important implications for understanding how endothelial TMEM16A contributes to ROS-dependent signaling in the vascular wall. Vascular NADPH oxidases in general, and oxidases in VSMCs in particular, are known to play key roles, especially Nox1-containing NADPH oxidase that predominates in VSMCs. 15 Moreover, the targeted disruption of TMEM16A in VSMCs was reported to result in lower basal blood pressure, 14 but it was not established whether this response was related to Nox1. We now demonstrate that Nox2, but not Nox1, can reverse TMEM16A-related Ang II-induced NADPH oxidase activation in the vascular endothelium and that the modulation of endothelial TMEM16A is sufficient to alter total vascular ROS generation and the hemodynamic response to Ang II. Additional studies need to determine how endothelial and VSMC TMEM16A together contribute to vascular ROS generation in the pathogenesis of vascular disease states.
Perspectives
Our present study provides evidence that TMEM16A plays a specific and critical role in mediating the hemodynamic response to Ang II through promoting Nox2-containing NADPH oxidasederived ROS generation. These results suggest that TMEM16A is a promising target for the treatment of endothelial dysfunction-associated cardiovascular diseases, such as hypertension, stroke, atherosclerosis, and diabetes mellitus.
